Decrease of plasma taurine in Gaucher disease and its sustained correction during enzyme replacement therapy

Amino Acids

Volumn 19, Issue 3-4, 2000, Pages 585-592

  Vom Dahl, S ^a   Monnighoff I ^a   Haussinger D ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Amino acids; Enzyme replacement therapy; Liver disease; Lysosomal storage disease; Macrophages

Indexed keywords

ALGLUCERASE; IMIGLUCERASE; TAURINE;

ADULT; AMINO ACID ANALYSIS; AMINO ACID BLOOD LEVEL; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME REPLACEMENT; FEMALE; GAUCHER DISEASE; HUMAN; LYSOSOME STORAGE DISEASE; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PRIORITY JOURNAL;

EID: 0033662610     PISSN: 09394451     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007260070008     Document Type: Conference Paper

References (30)

1. Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: Increased release of interleukin-6 and interleukin-10
2. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease
3. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease
4. Enzyme replacement therapy for Gaucher's disease
5. Differential diagnosis of (inherited) amino acid metabolism or transport disorders
6. Plasmaaminosaurenmuster bei Karzinomen des Gastrointestinaltrakts
7. Osmolyte strategy in human monocytes and macrophages-involvement of p38(MAPK) in hyperosmotic induction of betaine and myo-inositol transport
8. Selective effects of glucocerebroside (Gaucher's storage material) on macrophage cultures
9. Enzyme therapy in Gaucher disease type 1: Comparative efficacy of mannoseterminated glucocerebrosidase from natural and recombinant sources
10. Enzymic diagnosis in 27 cases with Gaucher's disease
11. Plasma and metabolic abnormalities in Gaucher's disease
12. Differential effects of enzyme supplementation on manifestations of Gaucher type 1 disease
13. Physiological actions of taurine
14. Plasma tumor necrosis factor-α (TNF-α) in Gaucher disease
15. Glucocerebrosidase for treatment of Gaucher's disease: First German long-term results
16. First long-term results of imiglucerase therapy of type I Gaucher disease
17. Enzyme therapy in Gaucher disease type I: Dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months
18. The role of osmolytes in intrahepatic cell-cell communication
19. Release of osmolytes from perfused rat liver on perivascular nerve stimulation: Alpha-adrenergic control of osmolyte efflux from parenchymal and non-parenchymal liver cells
20. Modulation of phagocytosis by anisoosmolarity and betaine in rat liver macrophages (Kupffer cells) and RAW 264.7 mouse macrophages
21. Osmoregulated taurine transport in H4IIE hepatoma cells and perfused rat liver
22. Taurine is an osmolyte in rat liver macrophages
23. Compatible organic osmolytes and osmotic modulation of inducible nitric oxide synthetase in RAW 264.7 mouse macrophages
24. Reduction of liver taurine in rats by β-alanine treatment increases carbon tetrachloride toxicity
25. Taurine protects against the cytotoxicity of hydrazine, 1,4, naphthoquinone and carbon tetrachloride in isolated rat hepatocytes
26. Cytoprotection by the osmolytes betaine and taurine in ischemia-reoxygenation injury in the perfused rat liver
27. Living with water stress: Evolution of osmolyte systems
28. Hyperosmolarity stimulates prostaglandin synthesis and cyclooxygenase-2 expression in activated rat liver macrophages
29. Modulation of tumor necrosis factor-α release by anisoosmolarity and betaine in rat liver macrophages (Kupffer cells)
30. Replacement therapy with imiglucerase for type 1 Gaucher's disease